Sevoflurane Suppresses Colon Cancer Cell Malignancy by Regulating circ-PI4KA

Suqing Sun1, Peng Wang1, Lijie Ren1

  • 1Department of Anesthesia, Tianjin Fifth Central Hospital, Tianjin, People's Republic of China.

Abstract

Insights

Sevoflurane (SEV) impacts colon cancer by downregulating circ-PI4KA, which increases miR-331-3p and inhibits LASP1. This mechanism reduces cancer cell malignancy and tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Colon cancer is a significant global health concern.
  • Circular RNAs (circRNAs) play crucial roles in various cancers, including colon cancer.
  • Sevoflurane (SEV), an anesthetic, has shown potential anti-cancer properties.

Purpose of the Study:

  • To investigate the effect of SEV on colon cancer cells.
  • To elucidate the role of circ-PI4KA in SEV-mediated anti-cancer activity.
  • To explore the molecular mechanism involving circ-PI4KA, miR-331-3p, and LASP1.

Main Methods:

  • Quantitative real-time PCR and Western blot to assess RNA and protein expression.
  • Cell proliferation, apoptosis, migration, and invasion assays to evaluate cellular functions.
  • Dual-luciferase reporter assays to confirm molecular interactions.
  • In vivo tumor formation assays to assess anti-cancer effects in a living organism.

Main Results:

  • Circ-PI4KA and LASP1 were upregulated, while miR-331-3p was downregulated in colon cancer.
  • SEV treatment decreased circ-PI4KA and LASP1 expression and increased miR-331-3p expression.
  • SEV inhibited colon cancer cell proliferation, migration, and invasion, and induced apoptosis by regulating circ-PI4KA.
  • Circ-PI4KA directly binds to miR-331-3p, which in turn targets LASP1.
  • SEV inhibited tumor growth in vivo by modulating the circ-PI4KA pathway.

Conclusions:

  • Circ-PI4KA acts as a sponge for miR-331-3p, leading to increased LASP1 expression and promoting colon cancer malignancy.
  • SEV attenuates colon cancer cell malignancy by downregulating circ-PI4KA, thereby upregulating miR-331-3p and inhibiting LASP1.
  • This study reveals a novel mechanism for SEV's anti-cancer effects and provides insights into surgery-mediated cancer therapy.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.5K